Abiopharma

Director CHAOUKI STEVEN M 🟢 acquired 27.0K shares (1 derivative) of MAIA Biotechnology, Inc. (MAIA) at $1.44 Transaction Date: Jun 30, 2026 | Filing ID: 000074

Director Guerrero Ramiro 🟢 acquired 26.4K shares (1 derivative) of MAIA Biotechnology, Inc. (MAIA) at $1.44 Transaction Date: Jun 30, 2026 | Filing ID: 000073

Director Louie Ngar Yee 🟢 acquired 32.6K shares (1 derivative) of MAIA Biotechnology, Inc. (MAIA) at $1.44 Transaction Date: Jun 30, 2026 | Filing ID: 000072

Director Luput Cristian 🟢 acquired 27.6K shares (1 derivative) of MAIA Biotechnology, Inc. (MAIA) at $1.44 Transaction Date: Jun 30, 2026 | Filing ID: 000071

Director Smith Stan 🟢 acquired 32.0K shares (1 derivative) of MAIA Biotechnology, Inc. (MAIA) at $1.44 Transaction Date: Jun 30, 2026 | Filing ID: 000070

MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer

MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University

MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial

MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial

MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion